ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Símbolo de cotizaciónPROK
Nombre de la empresaProKidney Corp
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoDr. Bruce Culleton, M.D.
Número de empleados204
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 30
Dirección2000 Frontis Plaza Blvd.
CiudadWINSTON-SALEM
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27103
Teléfono13369997028
Sitio Webhttps://prokidney.com/
Símbolo de cotizaciónPROK
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoDr. Bruce Culleton, M.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos